During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen ...

NSCLC, adding nivolumab to tivozanib in metastatic RCC underwhelms, and T-DXd shows improvement in HER2+ breast cancer with brain metastases.

During a Case-Based Roundtable® event, Virginia F. Borges, MD, MMSc, discussed treatment selection for a patient with ER+, ...

Anil Parwani, MD, PhD, discusses the challenges and opportunities he has encountered in either implementing or utilizing ...

During a Case-Based Roundtable® event, Ajay Nooka, MD, MPH, discussed adverse events related to talquetamab for multiple ...

Jacob E. Berchuck, MD, discusses research behind using a blood-based liquid biopsy over traditional PSMA PET scans presented ...

During a Case-Based Roundtable® event, Samer A. Al'Hadidi, MD, MS, discussed the CARTITUDE-4 trial of cilta-cel in patients ...

The decision to discontinue BTK inhibitor treatment for CLL is complex, with emerging data suggesting that time-limited ...

CF33-hNIS has gained FDA orphan drug designation for the treatment of cholangiocarcinoma and is currently being evaluated in ...

Following an investigational new drug application clearance from the FDA, a phase 1 trial plans to evaluate CD-001.

Sangeetha Venugopal, MD, MS, discussed the evolving landscape of acute myeloid leukemia treatment as well as unmet needs ...

At a median follow-up of 18 months, the OS rate was 95% and the DFS rate was 88%. 14 Long-term follow-up at a median of 53 ...